Wednesday, July 8, 2026

Drug profile · INN

floxuridine

floxuridine (FLOXURIDINE) is a thymidylate synthase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — floxuridine
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.89

Quick answer

floxuridine (FLOXURIDINE) is a thymidylate synthase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

Key facts

INN floxuridine
Brand FLOXURIDINE
Mechanism Thymidylate synthase inhibitor
Target Thymidylate synthase
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Thymidylate synthase inhibitor

Primary target: Thymidylate synthase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 2008-46 Phase 3 · First People's Hospital · Colorectal Neoplasms
  2. CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection Phase 2 · Jazz Pharmaceuticals Ireland · Colorectal Neoplasms

Related & competitor drugs

  1. pyrimethamine Dihydrofolate reductase inhibitor
  2. flucytosine Thymidylate synthase inhibitor
  3. raltitrexed Thymidylate synthase inhibitor

Frequently asked questions

What is floxuridine?

floxuridine (FLOXURIDINE) is a thymidylate synthase inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.

What is the brand name for floxuridine?

FLOXURIDINE is a marketed brand name for floxuridine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of floxuridine?

floxuridine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.